DK2445912T3 - Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme - Google Patents

Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme

Info

Publication number
DK2445912T3
DK2445912T3 DK10728648.6T DK10728648T DK2445912T3 DK 2445912 T3 DK2445912 T3 DK 2445912T3 DK 10728648 T DK10728648 T DK 10728648T DK 2445912 T3 DK2445912 T3 DK 2445912T3
Authority
DK
Denmark
Prior art keywords
degenerative
treatment
inflammatory diseases
compound useful
new compound
Prior art date
Application number
DK10728648.6T
Other languages
English (en)
Inventor
Christel Jeanne Marie Menet
Javier Blanc
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Application granted granted Critical
Publication of DK2445912T3 publication Critical patent/DK2445912T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK10728648.6T 2009-06-26 2010-06-25 Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme DK2445912T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22068509P 2009-06-26 2009-06-26
US29818810P 2010-01-25 2010-01-25
PCT/EP2010/059067 WO2010149771A1 (en) 2009-06-26 2010-06-25 Novel compound useful for the treatment of degenerative and inflammatory diseases

Publications (1)

Publication Number Publication Date
DK2445912T3 true DK2445912T3 (da) 2014-11-10

Family

ID=42340530

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14175887.0T DK2792677T3 (da) 2009-06-26 2010-06-25 Hidtil ukendt forbindelse til behandling af degenerative og inflammatoriske sygdomme.
DK10728648.6T DK2445912T3 (da) 2009-06-26 2010-06-25 Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14175887.0T DK2792677T3 (da) 2009-06-26 2010-06-25 Hidtil ukendt forbindelse til behandling af degenerative og inflammatoriske sygdomme.

Country Status (37)

Country Link
US (2) US8796457B2 (da)
EP (2) EP2445912B1 (da)
JP (1) JP5486084B2 (da)
KR (1) KR101712561B1 (da)
CN (1) CN102459261B (da)
AR (1) AR077221A1 (da)
AU (1) AU2010264635B2 (da)
BR (1) BRPI1014759A2 (da)
CA (1) CA2765988C (da)
CL (1) CL2011003276A1 (da)
CO (1) CO6491039A2 (da)
CR (1) CR20110673A (da)
CY (1) CY1119711T1 (da)
DK (2) DK2792677T3 (da)
DO (1) DOP2011000378A (da)
EA (1) EA020111B1 (da)
ES (2) ES2634325T3 (da)
HR (2) HRP20141057T1 (da)
HU (1) HUE034205T2 (da)
IL (1) IL216618A (da)
JO (1) JO3030B1 (da)
LT (1) LT2792677T (da)
MA (1) MA33447B1 (da)
ME (1) ME01916B (da)
MX (1) MX2011013451A (da)
NZ (1) NZ596836A (da)
PE (1) PE20120494A1 (da)
PL (2) PL2792677T3 (da)
PT (2) PT2792677T (da)
RS (1) RS53617B1 (da)
SG (1) SG177359A1 (da)
SI (2) SI2445912T1 (da)
SM (2) SMT201700333T1 (da)
TW (1) TWI469981B (da)
UY (1) UY32741A (da)
WO (1) WO2010149771A1 (da)
ZA (1) ZA201109502B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JP6129155B2 (ja) 2011-04-12 2017-05-17 ライジェル ファーマシューティカルズ， インコーポレイテッド 同種移植片拒絶反応を抑制する方法
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
KR20200039028A (ko) * 2011-10-11 2020-04-14 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
MX368511B (es) * 2012-06-22 2019-10-07 Galapagos Nv Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma.
JP6472803B2 (ja) 2013-09-05 2019-02-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ トリアゾロピリジン化合物、その組成物及び使用方法
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
SMT202300328T1 (it) * 2015-04-13 2023-11-13 Galapagos Nv Metodi per il trattamento di disturbi cardiovascolari
EP3492468B1 (en) 2016-07-26 2022-02-23 Suzhou Longbiotech Pharmaceuticals Co., Ltd. Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof
CN111479810B (zh) 2018-01-31 2022-11-22 珠海联邦制药股份有限公司 Jak抑制剂及其应用
KR20260109977A (ko) 2018-08-29 2026-07-13 리제너론 파아마슈티컬스, 인크. 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물
JP7542543B2 (ja) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
JP2022545312A (ja) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156037B1 (en) 1999-01-29 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
CA2487679A1 (en) * 2002-05-30 2003-12-11 Vertex Pharmaceuticals Incorporated Inhibitors of jak and cdk2 protein kinases
EP1601672B1 (en) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
EP1799680A2 (en) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridine derivatives as antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
JP5336375B2 (ja) * 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20090217316A1 (en) * 2008-02-22 2009-08-27 Binita Gupta Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات

Also Published As

Publication number Publication date
US8796457B2 (en) 2014-08-05
DOP2011000378A (es) 2012-02-15
JP5486084B2 (ja) 2014-05-07
TW201103937A (en) 2011-02-01
PE20120494A1 (es) 2012-05-17
TWI469981B (zh) 2015-01-21
HRP20171024T1 (hr) 2017-10-06
EP2445912A1 (en) 2012-05-02
KR20120059487A (ko) 2012-06-08
EA201270076A1 (ru) 2012-08-30
RS53617B1 (sr) 2015-04-30
CY1119711T1 (el) 2018-06-27
EP2792677B1 (en) 2017-04-26
BRPI1014759A2 (pt) 2016-04-19
CR20110673A (es) 2012-02-09
AR077221A1 (es) 2011-08-10
ZA201109502B (en) 2012-09-26
SG177359A1 (en) 2012-02-28
SI2445912T1 (sl) 2014-12-31
PL2792677T3 (pl) 2017-09-29
HUE034205T2 (en) 2018-01-29
SI2792677T1 (sl) 2017-08-31
SMT201700333T1 (it) 2017-09-07
CA2765988C (en) 2017-08-29
LT2792677T (lt) 2017-07-25
US20100331359A1 (en) 2010-12-30
SMT201400169B (it) 2015-01-15
KR101712561B1 (ko) 2017-03-06
IL216618A0 (en) 2012-02-29
HK1168098A1 (en) 2012-12-21
CO6491039A2 (es) 2012-07-31
CA2765988A1 (en) 2010-12-29
EA020111B1 (ru) 2014-08-29
PL2445912T3 (pl) 2015-02-27
AU2010264635A1 (en) 2011-12-22
EP2445912B1 (en) 2014-08-13
MX2011013451A (es) 2012-04-30
EP2792677A1 (en) 2014-10-22
JO3030B1 (ar) 2016-09-05
HK1202537A1 (en) 2015-10-02
US9505754B2 (en) 2016-11-29
HRP20141057T1 (en) 2015-03-13
JP2012530767A (ja) 2012-12-06
MA33447B1 (fr) 2012-07-03
CN102459261A (zh) 2012-05-16
ME01916B (me) 2015-05-20
WO2010149771A1 (en) 2010-12-29
CL2011003276A1 (es) 2012-08-31
PT2445912E (pt) 2014-11-07
NZ596836A (en) 2013-02-22
AU2010264635B2 (en) 2015-05-07
UY32741A (es) 2011-01-31
PT2792677T (pt) 2017-07-06
IL216618A (en) 2014-09-30
CN102459261B (zh) 2014-11-05
ES2634325T3 (es) 2017-09-27
ES2519170T3 (es) 2014-11-06
DK2792677T3 (da) 2017-07-10
US20150031671A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
BRPI1014759A2 (pt) composto útil para o tratamento de doenças degenerativas e inflamatórias
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
DK2419114T4 (da) Bakteriesammensætninger til profylakse og behandling af degenerative sygdomme
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK2183753T3 (da) Fremgangsmåder til køling
DK2853265T3 (da) Fremgangsmåder til at øge stabiliseringen af hypoxi-inducerbar faktor-1-alpha
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2794604T3 (da) Hidtil ukendte dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af inflammatoriske lidelse
DK2137537T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK2475372T4 (da) Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse
DK2480559T3 (da) Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
DK3354276T3 (da) Sammensætninger til behandlingen af gastrointestinal inflammation
DK2987507T3 (da) Fremgangsmåder til behandling af degenerative knogletilstande
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK2533761T3 (da) Fremgangsmåder og sammensætninger til fremstilling af aerosoler
DK2805746T3 (da) Alkylamido-forbindelser og anvendelser deraf
DK2307445T3 (da) Fremgangsmåde til fremstilling af caspofungin og mellemforbindelser heraf
DK2627656T3 (da) Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
DK3061766T3 (da) Sammensætninger og fremgangsmåder til behandlingen af sygdomme der involverer epitelcelleapoptose
DK2099446T3 (da) Fremgangsmåde til behandling af inflammatorisk tarmsygdom
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2462108T3 (da) Fremgangsmåde til fremstilling af pyrazolcarboxylsyreamider
DK2516359T3 (da) Fremgangsmåde til fremstilling af ethylbenzen